The Alteration and Significance of Erythropoietin Serum Levels in Preterm Infants with Retinopathy of Prematurity

Yang, Xiaofeng; Ze, Bi; Dai, Yi; Zhu, Li; Chen, Chao

doi:10.1055/s-0037-1601486

Cited by 7 publications

(8 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We hypothesised that low levels of erythropoietin, an oxygen-regulated growth hormone responsible for increasing haematocrit, may play an important role in suppressing retinal vascularisation in the early weeks of life and lead to the later development of severe ROP. Deficiency of erythropoietin was reported in the first phase of ROP in an animal model (27), and this finding was confirmed in preterm infants who developed ROP (27)(28)(29). Early supplementation with erythropoietin has been reported to prevent vessel loss and ischaemia in phase one and thereby suppressed later retinal neovascularisation in phase two ROP in an animal model (27).…”

Section: Discussionmentioning

confidence: 77%

Duration of anaemia during the first week of life is an independent risk factor for retinopathy of prematurity

et al. 2018

View full text Add to dashboard Cite

Aim This study evaluated the correlation between retinopathy of prematurity (ROP), anaemia and blood transfusions in extremely preterm infants. Methods We included 227 infants born below 28 weeks of gestation at King Edward Memorial Hospital, Perth, Australia, from 2014–2016. Birth characteristics and risk factors for ROP were retrieved, and anaemia and severe anaemia were defined as a haemoglobins of <110 g/L and <80 g/L, respectively. Logistic regression was used for the analysis. Results Retinopathy of prematurity treatment was needed in 11% of cases and the mean number of blood transfusions (p < 0.01), and mean number of weeks of anaemia (p < 0.001) and of severe anaemia (p < 0.05), had positive associations with ROP cases warranting treatment. In the multivariate logistic regression analysis, the best-fit model of risk factors included anaemic days during first week of life, with an odds ratio (OR) of 1.46% and 95% confidence interval (CI) of 1.16–1.83 (p < 0.05), sepsis during the first 4 weeks of life (OR 3.14, 95% CI 1.10–9.00, p < 0.05) and days of ventilation (OR 1.03, 95% CI 1.01–1.06, p < 0.05). Conclusion The duration of anaemia during the first week of life was an independent risk factor for ROP warranting treatment and preventing early anaemia may decrease this risk.

show abstract

Section: Discussionmentioning

confidence: 77%

Duration of anaemia during the first week of life is an independent risk factor for retinopathy of prematurity

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Holm et al 13,14 reported that serum EPO levels in the highest quartile on postnatal day 14 were associated with severe ROP that required treatment. Yang et al 15 reported that significantly lower EPO levels on postnatal day 28 were associated with infants that developed any degree of ROP. However, neither of those studies addressed the correlation between EPO levels and anaemia.…”

Section: Discussionmentioning

confidence: 99%

“…12 Moreover, serum EPO levels were elevated on postnatal day 14, in preterm infants that developed severe ROP 13,14 and reduced on postnatal day 28 in preterm infants that developed any degree of ROP. 15 Consequently, it remains unclear whether rhEPO treatment is a risk factor for ROP. 16–23 Some have suggested that the timing of rhEPO treatment is crucial.…”

Section: Introductionmentioning

confidence: 99%

Erythropoietin serum levels, versus anaemia as risk factors for severe retinopathy of prematurity

et al. 2018

View full text Add to dashboard Cite

BACKGROUND: Preterm infants with anaemia are treated with recombinant human erythropoietin (rhEPO). It is debated whether rhEPO treatment is a risk factor for retinopathy of prematurity (ROP). We evaluated longitudinal EPO and haemoglobin levels, blood transfusions and neonatal morbidities as risk factors for severe ROP. METHOD: This prospective study included 78 Swedish infants, born <28 weeks gestational age (GA), screened for ROP. We tested serum EPO levels on postnatal days 1,7, 14 and 28 and at postmenstrual ages 32, 36 and 40 weeks. Haemoglobin levels and blood transfusions were recorded during postnatal weeks 1–4. Anaemia was defined as haemoglobin ≤110 g/L. RESULTS: During postnatal week 1, infants with severe ROP requiring treatment (28%) more frequently developed anaemia (42.9% versus 8.0%, P = 0.003) and had higher mean EPO levels (postnatal day 7: 14.2 versus 10.8 mIU/mL, P = 0.003) compared to infants with no or less severe ROP not requiring treatment. In multivariable analyses, GA and anaemia during week 1 remained significant risk factors, but elevated EPO level postnatal day 7 was no longer significant. CONCLUSIONS: Among infants born <28 weeks GA, anaemia during week 1 was a significant risk factor for severe ROP requiring treatment but not elevated EPO levels.

show abstract

“…Infant-serum ELISA EPO On Day 28, decreased serum levels of EPO were determined to be independent factors for ROP prediction (50).…”

Section: Iconographymentioning

confidence: 99%

Novel Potential Biomarkers for Retinopathy of Prematurity

Tan

Wang

et al. 2022

Front. Med.

View full text Add to dashboard Cite

Retinopathy of prematurity (ROP) is the main risk factor for vision-threatening disease in premature infants with low birth weight. An accumulating number of independent studies have focused on ROP pathogenesis and have demonstrated that laser photocoagulation therapy and/or anti-VEGF treatment are effective. However, early diagnosis of ROP is still critical. At present, the main method of ROP screening is based on binocular indirect ophthalmoscopy. However, the judgment of whether ROP occurs and whether treatment is necessary depends largely on ophthalmologists with a great deal of experience. Therefore, it is essential to develop a simple, accurate and effective diagnostic method. This review describes recent findings on novel biomarkers for the prediction, diagnosis and prognosis of ROP patients. The novel biomarkers were separated into the following categories: metabolites, cytokines and growth factors, non-coding RNAs, iconography, gut microbiota, oxidative stress biomarkers, and others. Biomarkers with high sensitivity and specificity are urgently needed for the clinical applications of ROP. In addition, using non-invasive or minimally invasive methods to obtain samples is also important. Our review provides an overview of potential biomarkers of ROP.

show abstract

The Alteration and Significance of Erythropoietin Serum Levels in Preterm Infants with Retinopathy of Prematurity

Cited by 7 publications

References 24 publications

Duration of anaemia during the first week of life is an independent risk factor for retinopathy of prematurity

Duration of anaemia during the first week of life is an independent risk factor for retinopathy of prematurity

Erythropoietin serum levels, versus anaemia as risk factors for severe retinopathy of prematurity

Novel Potential Biomarkers for Retinopathy of Prematurity

Contact Info

Product

Resources

About